• SIGA Technologies outlined strategy to extend TPOXX franchise beyond smallpox treatment, targeting label expansion into post-exposure prophylaxis and new formulations, including pediatrics.
• Presentation highlighted TPOXX regulatory clearances in US, Canada, EU, UK, Japan; described product as targeting VP37 protein to block orthopoxvirus spread.
• Government contracting remained central, citing BARDA procurement awards totaling USD 461 million under a 2011-2018 contract, USD 546 million under a 2018-current contract, with USD 521 million recognized as revenue as of 3/31/2026.
• Company pointed to cumulative procurement of USD 30 million from US Department of Defense, USD 135 million from 30+ international customers; referenced 2020-2025 product revenue of about USD 980 million.
• Balance sheet positioning stressed no debt; presentation noted a USD 43 million cash dividend paid in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SIGA Technologies Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.